Cancer Research Meeting Calendar Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boulay, A.
Right arrow Articles by Lane, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boulay, A.
Right arrow Articles by Lane, H. A.
[Cancer Research 64, 252-261, January 1, 2004]
© 2004 American Association for Cancer Research

Regular Articles

Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells

Anne Boulay1, Sabine Zumstein-Mecker1, Christine Stephan1, Iwan Beuvink2, Frederic Zilbermann2, Roland Haller1, Sonja Tobler1, Christoph Heusser1, Terence O’Reilly1, Barbara Stolz1, Andreas Marti1, George Thomas2 and Heidi A. Lane1

1Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland, and 2Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The orally bioavailable rapamycin derivative RAD001 (everolimus) targets the mammalian target of rapamycin pathway and possesses potent immunosuppressive and anticancer activities. Here, the antitumor activity of RAD001 was evaluated in the CA20948 syngeneic rat pancreatic tumor model. RAD001 demonstrated dose-dependent antitumor activity with daily and weekly administration schedules; statistically significant antitumor effects were observed with 2.5 and 0.5 mg/kg RAD001 administered daily [treated tumor versus control tumor size (T/C), 23% and 23–30%, respectively], with 3–5 mg/kg RAD001 administered once weekly (T/C, 14–36%), or with 5 mg/kg RAD001 administered twice weekly (T/C, 36%). These schedules were well tolerated and exhibited antitumor potency similar to that of the cytotoxic agent 5-fluorouracil (T/C, 23%). Moreover, the efficacy of intermittent treatment schedules suggests a therapeutic window allowing differentiation of antitumor activity from the immunosuppressive properties of this agent. Detailed biochemical profiling of mammalian target of rapamycin signaling in tumors, skin, and peripheral blood mononuclear cells (PBMCs), after a single administration of 5 mg/kg RAD001, indicated that RAD001 treatment blocked phosphorylation of the translational repressor eukaryotic initiation factor 4E-binding protein 1 and inactivated the translational activator ribosomal protein S6 kinase 1 (S6K1). The efficacy of intermittent treatment schedules was associated with prolonged inactivation of S6K1 in tumors and surrogate tissues (>=72 h). Furthermore, detailed analysis of the dose dependency of weekly treatment schedules demonstrated a correlation between antitumor efficacy and prolonged effects (>=7 days) on PBMC-derived S6K1 activity. Analysis of human PBMCs revealed that S6K1 also underwent a concentration-dependent inactivation after RAD001 treatment ex vivo (>95% inactivation with 20 nM RAD001). In contrast, human PBMC-derived eukaryotic initiation factor 4E-binding protein 1 was present predominantly in the hypophosphorylated form and was unaffected by RAD001 treatment. Taken together, these results demonstrate a correlation between the antitumor efficacy of intermittent RAD001 treatment schedules and prolonged S6K1 inactivation in PBMCs and suggest that long-term monitoring of PBMC-derived S6K1 activity levels could be used for assessing RAD001 treatment schedules in cancer patients.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
RAD001 (everolimus), an orally bioavailable derivative of rapamycin, is a macrolide antifungal antibiotic that demonstrates potent antiproliferative effects against a variety of mammalian cell types. Specifically, RAD001 inhibits cytokine-driven lymphocyte proliferation (1) , as well as the proliferation of human tumor-derived cells grown either in culture or as tumors in animal models (2 , 3) . As a result of these properties, RAD001 is being clinically developed both as an immunosuppressant for prevention of allograft rejection (Certican; Ref. 1 ) and as a novel therapeutic in the fight against human cancer (2, 3, 4) .

RAD001, like rapamycin, binds with high affinity to a ubiquitous intracellular receptor, the immunophilin FKBP12. This complex specifically interacts with the mammalian target of rapamycin (mTOR) protein kinase; inhibiting downstream signaling events (5) . The mTOR kinase is a member of the phosphoinositide kinase-related kinase family, which consists of high molecular weight serine/threonine kinases involved in cell cycle checkpoint control (6) . Several lines of evidence suggest that mTOR acts as a sensor for stress (7) and the availability of amino acids (8, 9, 10) or intracellular ATP (11) . In the presence of mitogens and sufficient nutrients, mTOR relays a signal to translational regulators, specifically enhancing the translation of mRNAs encoding proteins essential for cell growth (12) and progression through the G1 to S transition (13 , 14) . Consistent with targeting the mTOR pathway, treatment of mammalian cells with rapamycin has been shown to inhibit these signaling events, mimicking a starvation phenotype (15) and leading to growth retardation and accumulation of cells in G1 phase (16) . The mechanism of growth stimulus and nutrient level integration by mTOR is, as yet, not fully understood. However, an increasing body of evidence suggests the involvement of the phosphatidylinositol 3'-kinase/Akt/TSC/Rheb pathway (12 , 17, 18, 19, 20, 21, 22, 23) . Indeed, it has been suggested that, in tumor cells, the activation status of the Akt pathway may be indicative of responsiveness to rapamycin or its derivatives (24, 25, 26, 27) .

mTOR is part of a multisubunit complex that contains the regulatory proteins raptor (28 , 29) and GßL (30) . The mTOR complex signals to at least two downstream effectors, the translational repressor protein eukaryotic initiation factor 4E (eIF-4E)-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase 1 (S6K1). These share an evolutionary conserved amino acid motif, the TOS motif, that functions as a docking site for raptor (31, 32, 33) . Binding of 4E-BP1 to the translational activator eIF-4E is modulated by mTOR-dependent phosphorylation of specific serine and threonine residues (5) . Ser37 and Ser46 are constitutively phosphorylated, acting as priming sites for the mitogen-induced, rapamycin-sensitive phosphorylation of Thr70 and Ser65 (34) . After a final phosphorylation event at Ser65, 4E-BP1 dissociates from eIF-4E (35) , thereby allowing the reconstitution of a translationally competent initiation factor complex (eIF-4F; Ref. 5 ). eIF-4F activation results in the translation of a subset of capped mRNA containing highly structured 5'-untranslated regions and encoding proteins involved in G1- to S-phase progression (13 , 14) . Mitogen-induced activation of the S6K1 is also dependent on mTOR function and has been implicated in the translational regulation of mRNAs possessing a 5'-terminal oligopyrimidine tract (36, 37, 38) . 5'-Terminal oligopyrimidine tract mRNAs are characterized by a stretch of 4–14 pyrimidines located at their extreme 5' terminus and typically encode ribosomal proteins as well as components of the translational machinery. Activation of S6K1 itself is also tightly regulated by hierarchical phosphorylation events, which are dependent on the activation of various signal transduction pathways and culminate in the phosphorylation of the rapamycin-sensitive site Thr389, an event closely paralleling kinase activation (12 , 39) . Immunopurified mTOR has been shown to autophosphorylate on Ser2481 (40) and to phosphorylate Ser37, Ser46, and Ser65 on 4E-BP1 in vitro (11 , 34 , 41 , 42) . However, some of these events have been demonstrated to be resistant to antiproliferative concentrations of rapamycin (40, 41, 42) . It is therefore unclear what role mTOR kinase activity plays per se in rapamycin-sensitive signaling events.

Because mTOR couples nutrient/growth factor availability to cell growth and proliferation in a variety of cell types, there is a potential for developing rapamycin derivatives such as RAD001 as novel inhibitors of the deregulated cell growth characteristic of human cancers. Consistent with this, RAD001 inhibits the proliferation of a wide variety of human solid tumor cell lines both in vitro in cell culture and in vivo in animal xenograft models (2 , 3 , 27 , 43 , 44) . Furthermore, antiproliferative effects of RAD001 in posttransplant lymphoproliferative disorder-like B cell lines have been observed in vitro and in vivo (45 , 46) . In the present study, we have demonstrated that RAD001 displays significant antitumor activity in the syngeneic CA20948 rat pancreatic tumor model. Equivalent activity was observed with daily and intermittent treatment schedules, suggesting the possibility of a therapeutic window allowing differentiation of antitumor activity from the immunosuppressive properties of this agent. Detailed biochemical analysis of the mTOR effectors 4E-BP1 and S6K1 in tumor, skin, and peripheral blood mononuclear cell (PBMC) extracts obtained from RAD001-treated rats suggests that modulation of 4E-BP1 activity and significant inactivation of S6K1 are associated with antitumor activity. Furthermore, the efficacy observed using intermittent treatment schedules is paralleled by long-term down-regulation of S6K1 activity in all three tissues. We also provide evidence that the duration of S6K1 inactivation in PBMCs correlates with the dose-dependent suppression of tumor growth observed with weekly regimens. Moreover, unlike 4E-BP1 phosphorylation, S6K1 activity can be reproducibly measured in human PBMCs and represents a potentially valuable pharmacodynamic biomarker by which to monitor RAD001 treatment schedules in cancer patients.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Drug Preparation.
RAD001 (everolimus) is a derivative of rapamycin [40-O-(2-hydroxyethyl)-rapamycin; Ref. 47 ]. For animal studies, RAD001 was formulated at 2% (w/v) in a microemulsion vehicle, which was diluted to the appropriate concentration in 5% (w/v) glucose solution just before administration by gavage. For in vitro and ex vivo analyses, RAD001 was prepared in DMSO before addition to cell culture or human volunteer blood samples.

Antitumor Efficacy Studies and Statistical Analyses.
Male Lewis rats were purchased from Iffa Credo (L’Abresque, France) and allowed food and water ad libitum. A suspension of CA20948 tumor cells (obtained from donor rats because this line is nonculturable in vitro) in Ham’s F-12 medium supplemented with 10% FCS, 0.1 g/100 ml NaHCO3, 1% penicillin, and 1% fungizone was injected s.c. into the left flank of rats. Treatment of randomized rats started when the tumors reached about 100 mm3. RAD001 was administered p.o. daily at 0.5 or 2.5 mg/kg (x6/week), twice weekly at 5 mg/kg, or weekly at 0.5, 1, 2, 3, or 5 mg/kg. A volume of vehicle equivalent to the highest dose of RAD001 administered in the experiment was used as a negative control. As a positive control, the cytotoxic agent 5-fluorouracil (5-FU; ICN Pharmaceuticals Inc., Costa Mesa, CA) was administered at a near maximum tolerated dose (15 mg/kg, i.v., 4x/week, 2 days treatment/2 days rest), which gives maximal antitumor effect. Tumors were measured every day or every other day with a caliper, and the volumes were calculated by using the formula of an ellipsoid [V = {pi}/6 (d1 x d2 x d3), where d1, d2, and d3 represent the three largest diameters]. Animals were also weighed the same day tumors were measured. The animals were sacrificed when either their tumor burden exceeded 25,000 mm3 or when skin overlaying the tumor exhibited evidence of necrosis. All protocols involving animals were approved by the Veterinäramt of Baselstadt, Switzerland.

Results are presented as mean ± 1 SEM or as percentage of T/C (mean increase of tumor volumes of treated animals divided by the mean increase of tumor volumes of control animals multiplied by 100). The statistical significance of differences between treatment and control groups were determined by ANOVA followed by the Dunnett test. Statistical analyses on body weight were performed by ANOVA followed by Tukey’s test, and for comparison between weight at start and end of the experiment for individual animals, the paired t test was used. The level of significance was set at P < 0.05. Statistical calculations were performed using SigmaStat 2.03 (Jandel Scientific).

Rat-Derived and Human Volunteer-Derived Tissue/PBMC Protein Extract Preparation.
CA20948 tumor-bearing rats were given 0.5, 1, 2, or 5 mg/kg RAD001 or an equivalent volume of vehicle. At the indicated times after administration, rats were sacrificed, and tumor and shaved skin samples (for 0.5 and 5 mg/kg RAD001 doses) were dissected and weighed. Samples were rinsed in ice-cold PBS and immediately extracted in ice-cold extraction buffer [50 mM Tris-HCl (pH 8.0), 120 mM NaCl, 20 mM NaF, 1 mM EDTA, 6 mM EGTA, 15 mM PPi, 30 mM p-nitrophenyl phosphate, 1 mM benzamidine, 0.2 mM phenylmethylsulfonyl fluoride, and 0.1% NP40] with a constant ratio of 45 mg tumor/ml extraction buffer and 90 mg skin/ml extraction buffer, using a PT3000 Polytron (probe PT-DA 3012/2S; Kinematica AG) or a hand-held PT2100 Polytron (probe PT-DA 2112/2EC), respectively. Lysates were cleared by centrifugation for 30 min at 12,000 x g at 4°C. Supernatants were subsequently aliquoted, snap frozen on dry ice, and stored at -80°C. In the case of skin samples, before further analysis, samples were centrifuged for 20 min at 436,000 x g at 4°C to remove the fat fraction.

Blood (for 0.5, 1, 2, and 5 mg/kg RAD001 doses) from tumor-bearing and non-tumor-bearing rats was withdrawn into syringes containing EDTA [0.5% (w/v) final] and then placed into an ice-cold tube and mixed. Unless otherwise stated, the blood from individual animals within the same treatment group was analyzed separately. The blood was immediately centrifuged for 20 min at 430 x g at 4°C. The PBMCs, deposited at the interface between the RBCs and the plasma, were collected and pelleted by centrifugation for 5 min at 3000 x g at 4°C. PBMCs were washed with 10 ml of ice-cold PBS and then repelleted by centrifugation for 5 min at 3000 x g at 4°C. Cell pellets were resuspended in ice-cold extraction buffer containing 1% NP40 at the fixed ratio of 500 µl extraction buffer/10 ml initial blood volume. The cells were sheared by vigorous pipetting and then centrifuged for 30 min at 12,000 x g at 4°C. Supernatants were aliquoted, snap frozen on dry ice, and stored at -80°C.

Human blood from healthy volunteers was collected under medical supervision into tubes containing either sodium citrate (BD Vacutainer 9NC; BD Vacutainer Systems, Plymouth, United Kingdom) or EDTA (BD Vacutainer K3E) as an anticoagulant. The blood was either immediately processed or, for ex vivo treatments, treated with 2, 20, and 200 nM RAD001 or DMSO vehicle for 30 min at room temperature. Human PBMCs were isolated and extracted as described for rat PBMCs.

A549 Cell Culture and Protein Extract Preparation.
A549 human lung carcinoma cells (CCL185) were obtained from the American Type Culture Collection (Manassas, VA) and cultured in RPMI 1640 medium (Amimed, Allschwil, Switzerland) supplemented with 10% FCS, 2 mM L-glutamine, and 100 µg/ml penicillin/streptomycin at 37°C and 5% CO2. Cell lysates were prepared as described previously (48) .

Immunoblot Analysis.
Cell lysates (30–40 µg) were electrophoretically resolved on denaturing SDS polyacrylamide gels (SDS-PAGE), transferred to polyvinylidene difluoride (Millipore Corp., Bedford, MA), and probed with the following primary antibodies: anti-S6 (provided by J. Mestan; Oncology Research, Novartis Pharma AG, Basel, Switzerland); anti-4E-BP1 (kindly provided by N. Sonenberg; McGill University, Montreal, Quebec, Canada); anti-eIF-4E (kindly provided by S. J. Morley; University of Sussex, Brighton, United Kingdom); anti-phospho-4E-BP1 Thr70, anti-S6K1, and anti-phospho-S6 Ser240/Ser244 (all from Cell Signaling Technology Inc., Beverly, MA); and anti-ß-tubulin (Tub2.1; Sigma, St. Louis, MO). "Decorated" proteins were revealed using horseradish peroxidase-conjugated antimouse or antirabbit immunoglobulins in conjunction with the enhanced chemiluminescence procedure (Amersham Pharmacia Biotech Inc., Buckinghamshire, United Kingdom).

Affinity Purification of 4E-BP1·eIF-4E Complexes with 7-Methyl-GTP-Sepharose.
Rat tumor (1 mg), skin (0.7 mg), or PBMC (0.25 mg) extracts were diluted to a final volume of 500 µl in ice-cold extraction buffer and adjusted to a final NP40 concentration of 0.1%. The 4E-BP1·eIF-4E complexes were affinity purified with 20 µl of 7-methyl-GTP-Sepharose beads (Amersham Pharmacia Biotech Inc., Piscataway, NJ) by gentle rotation for 2.5 h at 4°C. Proteins retained on the beads were washed twice with extraction buffer in the absence of NP40 and resuspended in 15 µl of Laemmli buffer. Denatured samples were subjected to 15% SDS-PAGE and transferred to polyvinylidene difluoride membranes. Membranes were first immunoblotted for 4E-BP1 protein, followed by stripping as described previously (49) and reprobing for eIF-4E protein (see above).

40SRibosomal S6 Kinase Assay.
Rat tumor (1 mg), skin (0.7 mg), or PBMC (0.25 mg) extracts were diluted to a final volume of 1 ml (tumor and skin) or 500 µl (PBMC) with ice-cold extraction buffer and adjusted to a final NP40 concentration of 1%. Human-derived PBMC extracts (0.8–1 mg) were diluted to a final volume of 750 µl with ice-cold extraction buffer (final NP40 concentration, 1%). In some experiments, human-derived PBMC extracts were first precleared with 20 µl of 50% protein A-Sepharose (Amersham Pharmacia Biotech, Uppsala, Sweden) by rotating for 20 min at 4°C. S6K1 was immunoprecipitated from all extracts by addition of 2.5 µl of the M5 S6K1-specific polyclonal antibody and incubation on ice for 1 h, followed by retrieval of immunocomplexes with 20 µl of 50% protein A-Sepharose. S6K1 activity was measured using rat liver 40S ribosomal subunits as a specific substrate, as described previously (50) , except that p-nitrophenyl phosphate was omitted in the reaction mixture. Phosphorylated S6 was resolved by 12.5% SDS-PAGE and analyzed using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). [{gamma}-32P]phosphate incorporation into S6 was quantified using ImageQuant (Molecular Dynamics). Where appropriate, the statistical significance of differences between treatment groups and untreated control groups was determined using ANOVA or ANOVA on ranks followed by the Dunnett test. The level of significance was set at P < 0.05. Statistical calculations were performed using SigmaStat 2.03 (Jandel Scientific). Coefficient of variation is defined as SD divided by the mean and multiplied by 100.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Intermittent RAD001 Treatment Schedules Display Antitumor Efficacy.
Short-term exposure to rapamycin in vitro has long-term antiproliferative effects on tumor cell lines (51) , suggesting that intermittent treatment schedules may retain antitumor activity. Furthermore, daily oral administration of RAD001 is effective in rat models of autoimmune disease and allotransplantation (47 , 52) , whereas we have found that weekly (5 mg/kg) RAD001 dosing schedules have reduced immunosuppressive properties in rats as compared with daily treatment (2.5 mg/kg): 66 ± 18% and 98 ± 1% inhibition of IgG antibody response after dinitrophenol-coupled keyhole limpet hemocyanogen immunization, respectively.3 With these observations in mind, we evaluated whether RAD001 treatment schedules, with potentially reduced immunosuppressive properties, could elicit antitumor responses. Daily versus intermittent RAD001 administration schedules were compared using the s.c. CA20948 rat pancreatic tumor model. Vehicle was used as a negative control, and the cytotoxic agent 5-FU was used as a positive control (Fig. 1Citation ; Table 1Citation , Experiment 1). RAD001 treatment at 0.5 or 2.5 mg/kg/day, six times a week, resulted in antitumor activity characterized by statistically significant inhibition of tumor growth as compared with vehicle controls [treated tumor versus control tumor size (T/C), 30% and 23%, respectively; P < 0.05 after 10 days of treatment; Fig. 1ACitation ; Table 1Citation , Experiment 1]. Statistically significant tumor growth suppression was also observed after intermittent administration of 5 mg/kg RAD001 twice a week (T/C, 36%) or once a week (T/C, 36%). Moreover, all RAD001 treatment schedules suppressed tumor growth to a similar extent as the cytotoxic 5-FU (T/C, 23%). Continued treatment with RAD001 after vehicle controls were sacrificed due to tumor burden led to a prolonged low tumor growth rate with all treatment schedules, resulting in similar tumor burden after 17 days of treatment as compared with 5-FU (Fig. 1A)Citation . For all treatment schedules, RAD001 was well tolerated, with no significant body weight loss or mortalities observed (Fig. 1BCitation ; Table 1Citation , Experiment 1). These results demonstrate that RAD001 is a well-tolerated antitumor agent in a rat model of pancreatic cancer and indicate a potential for intermittent administration schedules that may allow dissociation of antitumor from immunosuppressive effects.



View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Suppression of tumor growth by daily and intermittent dosing schedules of RAD001. Tumors were established in male Lewis rats by s.c. injection of CA20948 tumor suspension obtained from donor rats. Treatments started on day 4 after inoculation. Formulated RAD001 was diluted in a 5% glucose solution and administered p.o. daily at a dose of 0.5 or 2.5 mg/kg (qd x6, 6 times/week) or once (wk x1) or twice (wk x2) weekly at 5 mg/kg RAD001. Vehicle and 5-fluorouracil (5-FU x4; 4 times/week) were administered as negative and positive controls, respectively. Tumor volumes were measured (A), and rats were weighed (B) as described in "Materials and Methods." Vehicle control-treated rats were sacrificed on day 10 due to tumor burden. Data are means ± SEM (n = 7–8 animals/group). Stars represent P < 0.05 versus vehicle controls.

 

View this table:
[in this window]
[in a new window]

  		Table 1 Effect of daily and intermittent RAD001 administration on CA20948 rat pancreatic tumor-bearing rats

 
RAD001 Modulates 4E-BP1 and S6K1 Activity in Tumor, Skin, and PBMCs Obtained from CA20948 Pancreatic Tumor-Bearing Rats.
To investigate RAD001-specific effects on mTOR signaling in vivo, three CA20948 tumor-bearing rats were treated with vehicle or a single efficacious dose of RAD001 (5 mg/kg). Rats were sacrificed 24 h later, and protein extracts were prepared from tumors, skin, and PBMCs. By immunoblot analysis, mTOR could be detected in tumor and PBMC extracts; however, neither mTOR expression nor phosphorylation on Ser2448 was modified on RAD001 treatment.4 In contrast, 4E-BP1 exhibited a decrease in Thr70 phosphorylation in tumor, skin, and PBMC extracts (Fig. 2A)Citation , a phenomenon associated with changes in 4E-BP1 electrophoretic mobility, particularly striking in PBMCs. This observation is consistent with previous work demonstrating dephosphorylation of 4E-BP1 on Thr70 in tumors derived from mouse xenograft models after five daily treatments with an ester of rapamycin CCI-779 (1 h after last administration; Ref. 53 ). Interestingly, the phosphorylation of another rapamycin-sensitive residue (Ser65; Refs. 5 , 34 , and 35 ) was unaffected by RAD001 treatment,4 indicating that RAD001-insensitive phosphorylation of this site can occur as reported previously (54) .



View larger version (74K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. RAD001 administration inhibits mammalian target of rapamycin signaling in CA20948 tumor-bearing rats. S.c. CA20948 tumor-bearing rats received a single administration of an efficacious dose of RAD001 (5 mg/kg) or vehicle and were sacrificed 24 h after administration (3 rats/group). Tumors, skin, and PBMCs were individually prepared and extracted as described in "Materials and Methods." Results from individual rats are presented. A and C, total protein was subjected to electrophoresis followed by immunoblot analysis. Membranes were probed for eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and phospho-threonine 70 4E-BP1 [P-4E-BP1 (Thr70)] levels, with eukaryotic initiation factor 4E (eIF-4E) and ß-tubulin levels acting as loading controls (A) or ribosomal protein S6 kinase 1 protein, S6 40S ribosomal protein, and phospho-serine 240/244 S6 [P-S6 (Ser240/Ser244)] levels (C). B, the level of 4E-BP1 bound to eIF-4E was measured by purification of 4E-BP1·eIF-4E complexes on 7-methyl-GTP-Sepharose, as described in "Materials and Methods," followed by immunoblot analysis. D, ribosomal protein S6 kinase 1 was immunoprecipitated from equal amounts of total protein extract, and activity was measured by in vitro kinase assay using 40S ribosomal subunits as a specific substrate, as described in "Materials and Methods." Phosphorimages (32P-S6) and PhosphorImager quantifications of the kinase assay are presented. Data are means ± SD of n = 3 animals/group. Stars represent P < 0.05 versus vehicle-treated controls (Dunnett test).

 
To determine whether the decreased phosphorylation state of 4E-BP1 resulted in a change in functionality, the eIF-4E binding activity of 4E-BP1 was assessed using an in vitro 7-methyl-GTP-binding assay (Fig. 2B)Citation . Whereas similar levels of eIF-4E were recovered in the control- and RAD001-treated extracts, in two animals increased eIF-4E·4E-BP1 complex formation was clearly observed in skin and PBMC samples after RAD001 treatment. In tumor samples, two electrophoretically distinct forms of 4E-BP1 protein were bound to eIF-4E in vehicle control-treated rats (Fig. 2B)Citation . After RAD001 treatment, only the lower migrating form was found bound to eIF-4E, with an associated loss of the upper band consistent with reduced 4E-BP1 phosphorylation levels (Fig. 2A)Citation . A similar 4E-BP1 doublet with eIF-4E binding activity has been observed previously in proliferating cells/tissue (29 , 54) and presumably reflects differential 4E-BP1 phosphorylation states within the proliferating tumor.

To further assess the effect of RAD001 administration on the mTOR pathway, S6K1 protein and activity levels were also analyzed (Fig. 2, C and D)Citation . Whereas S6K1 protein levels were unaffected by RAD001 treatment (Fig. 2C)Citation , in vitro kinase assay using 40S ribosomal subunits as a substrate revealed a statistically significant reduction in S6K1 activity in all extracts [Fig. 2DCitation ; 83% (tumors), 80% (skin), and 75% (PBMC); all P < 0.05 versus vehicle-treated controls]. This reduction in S6K1 activity was associated with the dramatic dephosphorylation of its physiological substrate, 40S ribosomal protein S6, in tumor extracts (Fig. 2C)Citation . A similar reduction was not observed in skin and PBMC extracts because these tissues exhibited no detectable S6 phosphorylation in control animals. Interestingly, a reduction in S6 protein expression was observed in RAD001-treated skin, but not in tumor or PBMC extracts. A similar phenomenon has been reported previously in tumors after treatment of mice bearing human prostate cancer xenografts with CCI-779 (24) . Moreover, the translation of S6 (as a 5'-terminal oligopyrimidine tract mRNA) has been shown to be specifically inhibited by rapamycin in 3T3 cells (36) . It is not known why, in this model, RAD001 treatment only has effects on S6 expression in skin; however, differential downstream effects of mTOR pathway inhibition, depending on the tissue source, are a plausible possibility (54) . Taken together, these data demonstrate that both 4E-BP1 and S6K1 pathways are affected in tumors, skin, and PBMC samples obtained from CA20948 tumor-bearing rats after a single administration of an efficacious dose of RAD001.

Prolonged Inactivation of S6K1 in Tumors, Skin, and PBMCs Correlates with the Efficacy of Intermittent RAD001 Treatment Schedules.
To investigate whether the antitumor efficacy of intermittent RAD001 treatment schedules is associated with prolonged effects on the mTOR pathway, CA20948 tumor-bearing rats were treated with a single dose of RAD001 (5 mg/kg) or vehicle, and tumor, skin, and PBMC extracts were prepared 12, 24, 48, or 72 h after administration. Because S6K1 was significantly inactivated 24 h after a single RAD001 administration in all tissues analyzed (Fig. 2D)Citation , long-term effects on mTOR function were assessed using the 40S kinase assay (Fig. 3)Citation . Tumor and skin extracts were obtained from each of 3 rats/treatment group, whereas PBMC extracts were obtained from pooled blood from each treatment group. A dramatic reduction in S6K1 activity was already observed in tumors, skin, and PBMCs 12 h after RAD001 administration (91%, 91%, and 82% inhibition, respectively; all P < 0.05 versus untreated controls; Fig. 3Citation ). In contrast, treatment with vehicle did not significantly modulate S6K1 activity as compared with untreated controls (Fig. 3)Citation . Moreover, RAD001 treatment resulted in the sustained inactivation of S6K1 in all tissues. In tumors, statistically significant inhibition of S6K1 was maintained up to 48 h after administration, with some evidence of recovery after 72 h (80% and 62% inhibition at 48 and 72 h, respectively; Fig. 3ACitation ). In comparison, S6K1 derived from skin samples remained significantly inhibited for at least 72 h (72% inhibition at 72 h; Fig. 3BCitation ). Although a statistical analysis could not be performed on the pooled PBMC samples, S6K1 activity was also dramatically inhibited for up to 72 h in these samples (82% inhibition at 72 h; Fig. 3CCitation ). Thus, consistent with the antitumor efficacy of intermittent 5 mg/kg RAD001 treatment schedules in CA20948 tumor-bearing rats, a single administration of 5 mg/kg RAD001 resulted in long-term inactivation of S6K1 in tumors, skin, and PBMCs.



View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. RAD001 administration (5 mg/kg) causes prolonged inactivation of ribosomal protein S6 kinase 1 in tumors, skin, and PBMCs derived from CA20948 tumor-bearing rats. CA20948 tumor-bearing rats were treated once with 5 mg/kg RAD001 or vehicle (3 rats/group). After 12, 24, 48, and 72 h, tumor and skin samples were individually extracted. Blood obtained from rats within each treatment group was pooled, and peripheral blood mononuclear cells (PBMCs) were isolated and extracted. Assay of ribosomal protein S6 kinase 1 activity was performed using 40S ribosomal subunits as in vitro substrate. PhosphorImager quantifications of the S6 kinase assays are presented. A (Tumor) and B (Skin): data are means ± SD of n = 3 animals/group. Stars represent P < 0.05 versus untreated controls (Dunnett test). C (PBMC): data are means; error bars represent the range of duplicate assays.

 
The Antitumor Efficacy of Intermittent RAD001 Treatment Schedules Is Dose Dependent: Correlation Between Efficacy and Prolonged Effects on mTOR Effectors in Rat PBMCs.
Following the observation that intermittent RAD001 (5 mg/kg) treatment schedules significantly inhibited tumor growth, we explored the effect of RAD001 dose on the efficacy of weekly treatment schedules (Table 1Citation , Experiments 2 and 3). As expected, 5 mg/kg/week RAD001 significantly suppressed CA20948 tumor growth as compared with vehicle controls (T/C, 14% and 24% at 7 and 8 days, respectively; P < 0.05). In contrast, although 0.5 mg/kg RAD001 caused a significant inhibition of tumor growth when administered daily (T/C, 23%), weekly administration of the same dose did not significantly affect tumor growth (T/C, 48%; P > 0.05). This apparent dose dependency of weekly RAD001 schedules was confirmed by a more stringent analysis comprising doses between 5 and 0.5 mg/kg (Table 1Citation , Experiment 3). Statistically significant antitumor responses were observed with 3 and 2 mg/kg RAD001 (T/C, 36% and 32%, respectively), but not with 1 mg/kg (T/C, 45%). Interestingly, 3 mg/week elicited a similar antitumor response (T/C, 36%) as 0.5 mg/kg/day (x6/week; T/C, 30% and 23%). Because both these schedules involve administration of 3 mg/kg RAD001 per week, these data indicate that, with the same total RAD001 exposure, intermittent dosing schedules can elicit equivalent antitumor responses as daily schedules.

To further investigate the dose dependency of weekly schedules in terms of effects on mTOR signaling in a surrogate tissue, the duration of S6K1 inactivation in response to a single administration of 0.5 versus 5 mg/kg RAD001 was determined in PBMCs derived from three non-tumor-bearing rats (Fig. 4, A and B)Citation . Whereas in vehicle controls, no effect on S6K1 activity could be observed (24 h after administration), a single administration of 5 mg/kg RAD001 resulted in statistically significant, prolonged inactivation of the S6K1 for up to 7 days (99% and 86% inhibition after 24 h and 7 days, respectively; P < 0.05). In comparison, 0.5 mg/kg RAD001 caused a significant inhibition of PBMC-derived S6K1 activity 24 h after administration (88% inhibition); however, kinase activity began to recover after 48 h (75% inhibition) and was almost totally recovered after 7 days [23% inhibition; not significant (P > 0.05 versus controls)]. In contrast to effects on S6K1 activity, no effect on Thr70 phosphorylation or the electrophoretic mobility of 4E-BP1 was observed with the 0.5 mg/kg RAD001 dose, whereas decreased Thr70 phosphorylation and a shift to a lower migrating form were observed with the 5 mg/kg RAD001 dose (Fig. 4, C and D)Citation . The latter effect was maintained for 72 h, with evidence of recovery by 7 days.



View larger version (42K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Dose-dependent effects of RAD001 on ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) in peripheral blood mononuclear cells (PBMCs) obtained from non-tumor-bearing rats. Rats were treated with a single optimal (A and C) versus suboptimal (B and D) RAD001 dose (5 and 0.5 mg/kg, respectively) or vehicle (3 rats/group). At the times indicated, PBMC samples were collected and individually extracted. A and B, S6K1 was immunoprecipitated from equal amounts of protein extract, and S6K1 activity was assayed using 40S ribosomal subunits as a substrate. PhosphorImager quantification of the kinase assays are presented (means ± SD of n = 3 animals/group). Stars represent P < 0.05 versus untreated controls (Dunnett test). C and D, equal amounts of PBMC extracts were resolved by SDS-PAGE, transferred onto a polyvinylidene difluoride membrane, and probed for 4E-BP1 protein, phospho-threonine 70 4E-BP1 (P-4E-BP1 Thr70), or ß-tubulin as a loading control. Arrows denote hypophosphorylated (bottom arrow) and hyperphosphorylated (top arrow) forms of 4E-BP1 protein.

 
The above observations indicate that RAD001 has dose-dependent effects on the mTOR pathway in rat PBMCs. Moreover, long-term effects are associated with a RAD001 dose shown to have significant antitumor efficacy with intermittent treatment schedules. To confirm this hypothesis, a more stringent RAD001 titration was also performed to analyze effects on PBMC-derived S6K1 activity after a single administration of 0.5, 1, 2, or 5 mg/kg RAD001 (Fig. 5)Citation . In all cases, inactivation of S6K1 was observed 24 h after RAD001 administration. However, at RAD001 doses that do not elicit a significant antitumor response with weekly schedules (0.5 and 1 mg/kg; see Table 1Citation ), evidence of recovery of S6K1 activity was already observed at 72 h (34% and 13% recovery versus untreated controls, respectively) and was dramatic at 7 days [73% and 61%, respectively; no significant inhibition of S6K1 (P > 0.05 versus controls)]. In contrast, at RAD001 doses that do elicit a significant antitumor response with weekly schedules (2 and 5 mg/kg; see Table 1Citation ), minimal recovery was observed at 72 h (3% and 1%, respectively) or 7 days [30% and 12%, respectively; significant inhibition of S6K1 (P < 0.05 versus controls)]. These data confirm that long-term inactivation of PBMC-derived S6K1 correlates with the antitumor efficacy of weekly RAD001 treatment schedules.



View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Association between antitumor efficacy of weekly RAD001 schedules and long-term down-regulation of ribosomal protein S6 kinase 1 (S6K1) activity in rat peripheral blood mononuclear cells (PBMCs). Non-tumor-bearing rats were treated with a single RAD001 dose (0.5, 1, 2, or 5 mg/kg). At the times indicated, PBMC samples were collected and individually extracted and assayed for S6K1 activity. Data are presented as mean percentage recovery of S6K1 activity versus untreated control animals ± SEM of n = 3 or 6 S6K1 assays from different rat PBMC extracts. All data are derived from two separate experiments, except in the case of 1 mg/kg, where data from a single experiment are presented. Stars represent P < 0.05 versus untreated controls (ANOVA on ranks test).

 
S6K1 Activity Can Be Reproducibly Detected in Human PBMC Extracts: RAD001 Induces Concentration-Dependent S6K1 Inactivation Ex Vivo.
To evaluate the potential of using mTOR effectors as biomarkers to evaluate RAD001 treatment schedules, we assessed whether basal S6K1 activity could also be measured in human PBMC extracts obtained from healthy volunteers. Human blood was collected into tubes containing either sodium citrate or EDTA as an anticoagulant, and PBMC extracts were prepared. Subsequent assay of S6K1 activity demonstrated that activity could indeed be detected in nonchallenged human PBMCs derived from unrelated donors (Fig. 6A)Citation . Interestingly, S6K1 activity was reproducibly higher when the blood was initially collected in EDTA as compared with sodium citrate, a phenomenon potentially related to the different chelating properties of these anticoagulants. Using EDTA, a coefficient of variation of 10% was obtained among six assays on PBMC extracts prepared separately from the same blood donor, indicating good reproducibility of preparation (Fig. 6B)Citation . Accordingly, equivalent S6K1 protein levels were detected in the same extracts by immunoblot analysis (Fig. 6B)Citation . These results demonstrate that, in analogy with the rat PBMC data, basal S6K1 activity can be detected in human PBMCs. However, unlike control rat PBMC extracts (see Fig. 2ACitation ), there was no evidence of Thr70 phosphorylation in any of the human PBMC extracts analyzed,5 an observation correlating with the fact that most of the 4E-BP1 protein was present in the hypophosphorylated/fast migrating state (when compared with 4E-BP1 derived from proliferating human tumor cells; Fig. 7ACitation , DMSO). Ex vivo treatment of whole blood with 20 nM RAD001 for 30 min did not further increase protein mobility (Fig. 7ACitation , RAD001), suggesting that 4E-BP1 is largely active as a translational repressor in human PBMCs. Hence, unlike the situation in rat, this protein may not be applicable as a biomarker for monitoring RAD001-specific effects on mTOR signaling in human PBMCs.



View larger version (47K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Detection of ribosomal protein S6 kinase 1 (S6K1) activity in human peripheral blood mononuclear cells (PBMCs). Blood from healthy volunteers was withdrawn at the same time into tubes containing either sodium citrate or EDTA as an anticoagulant. PBMCs were immediately isolated and extracted. A, S6K1 was immunoprecipitated from equal amounts of PBMC protein extracts, and activity was assessed using 40S ribosomal subunits as a substrate. PhosphorImager quantifications are presented and represent basal S6K1 activity (means of duplicate assays of a single sample) from two unrelated donors. B, blood from a single volunteer was withdrawn into tubes containing EDTA as an anticoagulant and was split into six equal fractions. PBMCs were prepared separately and extracted from each blood fraction, and extracts were simultaneously assayed for S6K1 kinase activity. Phosphorimages (32P-S6) and PhosphorImager quantifications (graph) of duplicate kinase assays are presented. As internal controls, equal amounts of PBMC protein extracts were analyzed by immunoblot for S6K1 and ß-tubulin protein levels.

 


View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 7. Effects of ex vivo RAD001 treatment on ribosomal protein S6 kinase 1 activity and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) mobility in human PBMCs. A, blood was collected from two unrelated donors using EDTA as an anticoagulant and treated ex vivo with DMSO vehicle or 20 nM RAD001 for 30 min at room temperature, followed by PBMC isolation and extraction. Equal amounts of PBMC protein extracts were resolved by SDS-PAGE and transferred onto a polyvinylidene difluoride membrane. The membrane was probed for 4E-BP1 protein, with ß-tubulin as a loading control. Human lung adenocarcinoma tumor cell lines lysates (Control; A549) were included as an example of 4E-BP1 mobility in a highly proliferative human cell population. B, blood was collected from two unrelated donors using EDTA as an anticoagulant and treated ex vivo with 2, 20, or 200 nM RAD001 or DMSO vehicle for 30 min at room temperature, followed by PBMC isolation and extraction. Ribosomal protein S6 kinase 1 was immunoprecipitated from equal amounts of PBMC protein extract, and activity was assessed in vitro using 40S ribosomal subunits as a substrate. PhosphorImager quantifications of the kinase assay are presented and represent means of duplicate assays of a single sample.

 
To assess whether human PBMC-derived S6K1 is inactivated in the presence of RAD001, whole blood from two unrelated healthy volunteers was treated ex vivo with either DMSO vehicle or increasing concentrations of RAD001 for 30 min, followed by isolation, extraction, and assay of PBMC-derived S6K1 activity (Fig. 7B)Citation . Treatment with 2 nM RAD001 diminished PBMC-derived S6K1 activity as compared with DMSO vehicle controls (44% and 63% inhibition in donor 1 and 2, respectively). Furthermore, increasing RAD001 concentrations led to almost complete inactivation of S6K1 (>=95% inhibition with >=20 nM RAD001 in donor 1 and 2). These results demonstrate that RAD001 treatment of human blood ex vivo results in a concentration-dependent inactivation of PBMC-derived S6K1, supporting the notion that changes in PBMC-derived S6K1 activity could serve as a biomarker when assessing treatment schedules with rapamycin derivatives such as RAD001 in clinical trials for cancer.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The mTOR pathway plays a major role in cell proliferation by coupling cell growth with G1-S progression. Compounds targeting the mTOR pathway have potential, therefore, for application in cancer treatment modalities (2 , 3 , 4) . In this context, RAD001 potently inhibits the proliferation of numerous tumor cell lines in vitro and inhibits the growth of a range of human xenografts in nude mice (2 , 27 , 43, 44, 45, 46) .6 Rapamycin and the rapamycin ester CCI-779 also present antitumor activity in a number of animal models of cancer (2 , 24, 25, 26 , 53 , 55, 56, 57, 58, 59) . However, although human pancreatic tumors have been reported in abstract form to be sensitive to CCI-779 (reviewed in Ref. 2 ), and mTOR/S6K1 signaling appears to be required for pancreatic cancer cell proliferation (60 , 61) , the work presented here is the first full publication demonstrating significant antitumor efficacy of a rapamycin derivative in an animal model of pancreatic cancer. Orally administered RAD001 was found to be well tolerated and to elicit antitumor potency equivalent to that of the cytotoxic agent 5-FU. Moreover, similar responses were achieved with daily or weekly RAD001 administrations, indicating that frequent drug administration is unnecessary to maintain an antitumor response. Although weekly rapamycin dosing schedules have been used previously (55 , 56) , a comparative analysis addressing the efficacy of daily versus weekly administration had not been performed. The fact that weekly RAD001 administration produces statistically significant antitumor responses in the CA20948 model is supported by a number of experimental observations. First, in vitro pulse treatment with either RAD001 (43) or rapamycin (51) causes prolonged down-regulation of the mTOR pathway in tumor cell lines. Indeed, Hosoi et al. (51) postulated that this phenomenon was due to the slow dissociation rate of the rapamycin·FKBP12 complex. Second, prolonged effects of CCI-779 on xenograft tumor growth were evident after cessation of daily treatment schedules (24 , 53 , 57) , and antitumor responses have been reported in Phase I clinical trials with weekly CCI-779 administration (2 , 4) .

One advantage of administering RAD001 intermittently in oncology is the avoidance of prolonged immunosuppression (1) . In this context, the minimal effective dose of RAD001 in stringent rat kidney and heart allotransplantation models is >=5 mg/kg administered daily (47 , 52) . Moreover, the immunosuppressive capacity of RAD001 (everolimus in combination with cyclosporin) in transplant patients has been related to maintenance of blood drug trough levels (1 , 62) , suggesting that constant drug exposure is required to provide clinically relevant immunosuppression. The demonstration that weekly administration of RAD001 (at doses of 2–5 mg/kg) is sufficient to elicit a significant antitumor response indicates that the above premise does not apply to oncology. Indeed, in support of this notion, as compared with daily RAD001 administration (2.5 mg/kg), a 5 mg/kg weekly RAD001 regimen allows a 20-fold higher T-cell-dependent antibody response, as measured by serum IgG antibody titers after immunization of rats with dinitrophenol-coupled keyhole limpet hemocyanogen.3 Hence, intermittent dosing allows for differentiation between immunosuppressive and antitumor effects, a possibility also suggested from preliminary clinical data (2 , 4) . The basis of this is presumably related to the biology of T cells as compared with tumor cells. In this respect, rapamycin potently prevents resting T cells from entering the cell cycle in response to interleukin 2 but has little effect on proliferating T cells (63 , 64) . This may explain why constant drug exposure is required in the immunosuppression setting, as opposed to the antitumor setting where the proliferation of cycling tumor cells is potently inhibited (2 , 4) for long periods (51) . This possibility is worthy of further investigation.

A limited analysis of the effects of rapamycin derivatives on mTOR effectors in tumor material derived from xenograft models was reported previously (24 , 53) . Until now, however, a comprehensive analysis had not been performed. Similarly, the possibility that the efficacy of intermittent treatment schedules correlates with long-term effects on the mTOR pathway in tumors and surrogate tissues had not been addressed. This prompted us to profile RAD001-mediated effects on mTOR signaling in CA20948 tumors and normal rat tissues. Mitogen-induced, multisite phosphorylation of the translational suppressor protein 4E-BP1 is known to cause its release from the initiation factor eIF-4E, thereby facilitating formation of the eIF-4F initiation complex and derepression of cap-dependent mRNA translation (2 , 5) . Indeed, the 4E-BP1 protein has been proposed to be a direct substrate for the mTOR kinase (34 , 41 , 42) . Moreover, rapamycin treatment of cell lines decreases 4E-BP1 phosphorylation, resulting in increased affinity for eIF-4E in vitro (2 , 5) . Consistent with these observations, a single administration of 5 mg/kg RAD001 to three tumor-bearing rats reproducibly inhibited 4E-BP1 phosphorylation in tumors, skin, and PBMCs at 24 h, in accordance with changes in 4E-BP1 electrophoretic mobility and increased 4E-BP1·eIF-4E association. In the same animals, S6K1 signaling was virtually abolished in all tissues. The physiological downstream target of the S6K1 is the S6 40S ribosomal protein (12 , 65) . Hence, reductions in S6 phosphorylation are expected to parallel S6K1 inactivation, as observed in CA20948 tumor extracts. However, because S6 phosphorylation could not be detected in either skin or PBMC control extracts, no such correlation could be made in these tissues. This failure to detect S6 phosphorylation could reflect a reduced proliferation index as compared with the aggressively growing CA20948 tumors. Strikingly, and in agreement with previous in vitro analyses (43 , 51) , tumors, skin, and PBMC extracts derived from rats treated with a single 5 mg/kg RAD001 dose demonstrated prolonged inactivation of the S6K1 for >=72 h. Taken together, these data suggest that RAD001-specific effects on 4E-BP1 and S6K1 activity can be reproducibly observed in tumors and surrogate tissues. Moreover, long-term effects of RAD001 on S6K1 activity occur with a dose of RAD001 known to elicit significant antitumor responses with intermittent treatment schedules.

The observation that the mTOR pathway is affected for long periods of time in tumors and PBMCs is consistent with preliminary pharmacokinetic studies performed in CA20948 tumor-bearing rats. Pharmacokinetic measurements after a single RAD001 administration (5 mg/kg, over a 72 h period) demonstrated good bioavailability/efficient tumor penetration (maximal concentrations in blood and tumor, ~200 and ~700 nM, respectively) and prolonged residency [RAD001 half-life, ~20–22h.7 Unfortunately, a precise correlation of pharmacokinetic parameters with antiproliferative effects in tumors is difficult in this model because of the inability to determine in vitro IC50 values with the nonculturable CA20948 line. However, the efficient tumor accumulation and relatively long half-life of RAD001 provide further rationale for the long-term effects observed in this model.

Sequential tumor sampling is difficult in the clinical setting, necessitating some reliance on surrogate tissue to assess pharmacodynamic effects of antitumor agents. For this reason, the possibility of using PBMCs as a source for biomarker analysis when assessing RAD001 treatment schedules was evaluated. Detailed efficacy experiments demonstrated that antitumor response to weekly administration of RAD001 was dose dependent. Moreover, significant antitumor responses were associated with long-term effects on the mTOR pathway in PBMCs. Interestingly, PBMC-derived 4E-BP1 was unaffected by a suboptimal RAD001 dose (0.5 mg/kg), despite transient effects on S6K1 activity. This suggests that S6K1 is a more sensitive marker of RAD001 exposure in PBMCs than 4E-BP1. Indeed, all doses of RAD001 evaluated elicited a dramatic inhibition of PBMC-derived S6K1 after 24 h. However, the rate at which S6K1 activity subsequently recovered differed, with RAD001 doses that were efficacious with weekly schedules causing more profound long-term effects on S6K1 activity (>=7 days). The demonstration that the mTOR pathway is affected in PBMCs for a week after administration of 5 mg/kg RAD001 may be interpreted as being contrary to our observations that weekly treatment with this dose is suboptimal in terms of suppression of T-cell-dependent antigen responses. To reconcile these observations, one has to consider that T- and B-cell proliferative responses to foreign antigen presentation occur mainly in the secondary lymphoid organs (64) . Here we assayed S6K1 derived from PBMCs, a source that does not reflect the situation in these organs. We therefore speculate that, using weekly schedules, there is a possibility to recover T-cell responses, a phenomenon that may also reflect the pharmacokinetic characteristics of RAD001.

To most efficiently exploit the pharmacological profile of targeted agents such as RAD001, it is important to carefully monitor the dose given to a cancer patient, especially considering the observation that rapamycin can be less effective as an antitumor agent in animal models if overdosed (59) . The ease of human PBMC preparation suggests that this could be a valuable surrogate tissue when establishing treatment regimens for RAD001 in clinical trials for oncology. Based on this premise, S6K1 activity could be reproducibly assayed in PBMC extracts prepared from healthy volunteers, and RAD001 treatment of whole blood ex vivo resulted in concentration-dependent inactivation of the kinase. In contrast, despite promising results in tumor extracts derived from xenograft models (53) and suggestions that 4E-BP1 phosphorylation could be used as a confirmatory measure of mTOR inhibition in PBMCs (66) , we have shown that 4E-BP1 phosphorylation cannot be detected in human PBMCs. During the revision of this manuscript, others (66 , 67) also reported on the potential for PBMC-derived S6K1 activity measurements to aid pharmacodynamic evaluation of rapamycin derivatives. Analysis of cancer patient-derived PBMCs after i.v. administration of 25, 75, and 250 mg CCI-779 demonstrated inactivation of PBMC-derived S6K1 for up to 8 days, with no evidence of dose dependency at the doses used (66, 67, 68) . Although a limited feasibility study in nine patients indicated an association between time to disease progression and the degree of inhibition of S6K1 24 h after CCI-779 administration, no conclusions were drawn regarding the predictive nature of this biomarker or associated implications of the long-term S6K1 inactivation observed in patients (67) . Our data provide a strong experimental rationale for analyzing long-term effects on PBMC-derived S6K1 activity when establishing weekly administration schedules. Indeed, recent Phase I trials with weekly administration of RAD001 in patients with advanced cancer have demonstrated a clear association between RAD001 dose and the recovery of PBMC-derived S6K1 activity over a >=7-day period (69) . The value of these observations in terms of prediction of patient response is now being pursued in clinical trials of RAD001 in oncology.


   ACKNOWLEDGMENTS
 
We thank Dr. N. Sonenberg (McGill University, Montreal, Canada) for kindly supplying the 4E-BP1 antibody, Dr. S. J. Morley (University of Sussex, Brighton, United Kingdom) for kindly supplying the eIF-4E antibody, and Dr. J. Mestan (Oncology Research, Novartis Pharma AG, Basel, Switzerland) for supplying the S6 antibody. We thank Drs. W. Schuler and R. Sedrani (Transplantation Research, Novartis Pharma AG) for providing RAD001 and much appreciated advice. We thank Beatrice Engriser (Johnson Control, Basel, Switzerland) for her contribution to this study, and Drs. S. M. Maïra and P. Fuerst (Oncology Research, Novartis Pharma AG) for comments on the manuscript. We extend special thanks to the volunteers who provided blood samples for this study.


   FOOTNOTES
 
Grant support: Iwan Beuvink, Frederic Zilbermann, and George Thomas were supported by Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Anne Boulay and Sabine Zumstein-Mecker contributed equally to this work.

Requests for reprints: Heidi A. Lane, Novartis Institutes for BioMedical Research Basel, Oncology, Novartis Pharma AG, WKL-125.13.17, CH-4002 Basel, Switzerland. Phone: 41-61-696-5438; Fax: 41-61-696-3835; E-mail: heidi.lane{at}pharma.novartis.com

3 T. O’Reilly, H. A. Lane, and C. Heusser, unpublished data. Back

4 A. Boulay and H. A. Lane, unpublished data. Back

5 A. Boulay, S. Zumstein-Mecker, and H. A. Lane, unpublished data. Back

6 A. Boulay, T. O’Reilly, and H. A. Lane, unpublished data. Back

7 T. O’Reilly and L. McMahon, unpublished data. Back

Received 12/18/02. Revised 9/10/03. Accepted 10/30/03.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Nashan B. Early clinical experience with a novel rapamycin derivative. Ther. Drug Monit., 24: 53-58, 2002.[CrossRef][Medline]
  2. Huang S., Houghton P. J. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr. Opin. Investig. Drugs, 3: 295-304, 2002.[Medline]
  3. Mita M. M., Mita A., Rowinski E. K. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin. Breast Cancer, 4: 126-137, 2003.[Medline]
  4. Hidalgo M., Rowinsky E. K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 19: 6680-6686, 2000.[CrossRef][Medline]
  5. Gingras A. C., Raught B., Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev., 15: 807-826, 2001.[Free Full Text]
  6. Tibbetts R. S., Abraham R. T. PI3K-related kinases: roles in cell-cycle regulation and DNA damage responses Gutkind J. S. eds. . Signaling Networks and Cell Cycle Control: The Molecular Basis of Cancer and Other Diseases, Vol. 5: 267-301, Humana Press Totowa, NJ 2000.[CrossRef]
  7. Desai B. N., Myers B. R., Schreiber S. L. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc. Natl. Acad. Sci. USA, 99: 4319-4324, 2002.[Abstract/Free Full Text]
  8. Hara K., Yonezawa K., Weng Q. P., Kozlowski M. T., Belham C., Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem., 273: 14484-14494, 1998.[Abstract/Free Full Text]
  9. Xu G., Kwon G., Marshall C. A., Lin T. A., Lawrence J. C., Jr., McDaniel M. L. Branched-chain amino acids are essential in the regulation of PHAS-I and p70 S6 kinase by pancreatic ß-cells. A possible role in protein translation and mitogenic signaling. J. Biol. Chem., 273: 28178-28184, 1998.[Abstract/Free Full Text]
  10. Iiboshi Y., Papst P. J., Kawasome H., Hosoi H., Abraham R. T., Houghton P. J., Terada N. Amino acid-dependent control of p70(s6k). involvement of tRNA aminoacylation in the regulation. J. Biol. Chem., 274: 1092-1099, 1999.[Abstract/Free Full Text]
  11. Dennis P. B., Jaeschke A., Saitoh M., Fowler B., Kozma S. C., Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science (Wash. DC), 294: 1102-1105, 2001.[Abstract/Free Full Text]
  12. Dufner A., Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp. Cell Res., 253: 100-109, 1999.[CrossRef][Medline]
  13. Hashemolhosseini S., Nagamine Y., Morley S. J., Desrivieres S., Mercep L., Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem., 273: 14424-14429, 1998.[Abstract/Free Full Text]
  14. West M. J., Stoneley M., Willis A. E. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway. Oncogene, 17: 769-780, 1998.[CrossRef][Medline]
  15. Peng T., Golub T. R., Sabatini D. M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Cell. Biol., 22: 5575-5584, 2002.[Abstract/Free Full Text]
  16. Fingar D. C., Salama S., Tsou C., Harlow E., Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev., 16: 1472-1487, 2002.[Abstract/Free Full Text]
  17. Scott P. H., Brunn G. J., Kohn A. D., Roth R. A., Lawrence J. C., Jr. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA, 95: 7772-7777, 1998.[Abstract/Free Full Text]
  18. Nave B. T., Ouwens M., Withers D. J., Alessi D. R., Shepherd P. R. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J., 344: 427-431, 1999.
  19. Sekulic A., Hudson C. C., Homme J. L., Yin P., Otterness D. M., Karnitz L. M., Abraham R. T. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res., 60: 3504-3513, 2000.[Abstract/Free Full Text]
  20. Inoki K., Li Y., Zhu T., Wu J., Guan K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol., 4: 648-657, 2002.[CrossRef][Medline]
  21. Potter C. J., Pedraza L. G., Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol., 4: 658-665, 2002.[CrossRef][Medline]
  22. Garami A., Zwartkruis F. J., Nobukuni T., Joaquin M., Roccio M., Stocker H., Kozma S. C., Hafen E., Bos J. L., Thomas G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell, 11: 1457-1466, 2003.[CrossRef][Medline]
  23. Inoki K., Li Y., Xu T., Guan K. L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev., 17: 1829-1834, 2003.[Abstract/Free Full Text]
  24. Neshat M. S., Mellinghoff I. K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J. J., Wu H., Sawyers C. L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA, 98: 10314-10319, 2001.[Abstract/Free Full Text]
  25. Podsypanina K., Lee R. T., Politis C., Hennessy I., Crane A., Puc J., Neshat M., Wang H., Yang L., Gibbons J., Frost P., Dreisbach V., Blenis J., Gaciong Z., Fisher P., Sawyers C., Hedrick-Ellenson L., Parsons R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in PTEN+/- mice. Proc. Natl. Acad. Sci. USA, 98: 10320-10325, 2001.[Abstract/Free Full Text]
  26. Shi Y., Gera J., Hu L., Hsu J. H., Bookstein R., Li W., Lichtenstein A. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res., 62: 5027-5034, 2002.[Abstract/Free Full Text]
  27. Lane H. A., Boulay A., Hattenberger M., Maira S-M., Thomas G., Merlo A., O’Reilly T. The orally active rapamycin derivative RAD001 has potential as an antitumor agent with a broad antiproliferative activity: PTEN as a molecular determinant of response. Proc. Am. Assoc. Cancer Res., 44: 314 2003.
  28. Kim D. H., Sarbassov D. D., Ali S. M., King J. E., Latek R. R., Erdjument-Bromage H., Tempst P., Sabatini D. M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell, 110: 163-175, 2002.[CrossRef][Medline]
  29. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., Tokunaga C., Avruch J., Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell, 110: 177-189, 2002.[CrossRef][Medline]
  30. Kim D. H., Sarbassov dos D., Ali S. M., Latek R. R., Guntur K. V., Erdjument-Bromage H., Tempst P., Sabatini D. M. GßL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell, 11: 895-904, 2003.[CrossRef][Medline]
  31. Schalm S. S., Blenis J. Identification of a conserved motif required for mTOR signaling. Curr. Biol., 12: 632-639, 2002.[CrossRef][Medline]
  32. Schalm S. S., Fingar D. C., Sabatini D. M., Blenis J. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol., 13: 797-806, 2003.[CrossRef][Medline]
  33. Nojima H., Tokunaga C., Eguchi S., Oshiro N., Hidayat S., Yoshino K., Hara K., Tanaka N., Avruch J., Yonezawa K. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem., 278: 15461-15464, 2003.[Abstract/Free Full Text]
  34. Gingras A. C., Gygi S. P., Raught B., Polakiewicz R. D., Abraham R. T., Hoekstra M. F., Aebersold R., Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev., 13: 1422-1437, 1999.[Abstract/Free Full Text]
  35. Mothe-Satney I., Brunn G. J., McMahon L. P., Capaldo C. T., Abraham R. T., Lawrence J. C., Jr. Mammalian target of rapamycin-dependent phosphorylation of PHAS-I in four (S/T)P sites detected by phospho-specific antibodies. J. Biol. Chem., 275: 33836-33843, 2000.[Abstract/Free Full Text]
  36. Jefferies H. B., Reinhard C., Kozma S. C., Thomas G. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc. Natl. Acad. Sci. USA, 91: 4441-4445, 1994.[Abstract/Free Full Text]
  37. Jefferies H. B., Fumagalli S., Dennis P. B., Reinhard C., Pearson R. B., Thomas G. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J., 16: 3693-3704, 1997.[CrossRef][Medline]
  38. Meyuhas O. Synthesis of the translational apparatus is regulated at the translational level. Eur. J. Biochem., 267: 6321-6330, 2000.[Medline]
  39. Pearson R. B., Dennis P. B., Han J. W., Williamson N. A., Kozma S. C., Wettenhall R. E., Thomas G. The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J., 14: 5279-5287, 1995.[Medline]
  40. Peterson R. T., Beal P. A., Comb M. J., Schreiber S. L. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J. Biol. Chem., 275: 7416-7423, 2000.[Abstract/Free Full Text]
  41. Brunn G. J., Hudson C. C., Sekulic A., Williams J. M., Hosoi H., Houghton P. J., Lawrence J. C., Jr., Abraham R. T. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (Wash. DC), 277: 99-101, 1997.[Abstract/Free Full Text]
  42. Burnett P. E., Barrow R. K., Cohen N. A., Snyder S. H., Sabatini D. M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA, 95: 1432-1437, 1998.[Abstract/Free Full Text]
  43. Beuvink I., O’Reilly T., Zumstein-Mecker S., Zilbermann F., Sedrani R., Kozma S. C., Thomas G., Lane H. A. Antitumor activity of RAD001, an orally active rapamycin derivative. Proc. Am. Assoc. Cancer Res., 42: 366 2001.
  44. O’Reilly T., Vaxelaire J., Muller M., Fiebig H. H., Hattenberger M., Lane H. A. In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models. Proc. Am. Assoc. Cancer Res., 43: 71 2002.
  45. Majewski M., Korecka M., Kossev P., Li S., Goldman J., Moore J., Silberstein L. E., Nowell P. C., Schuler W., Shaw L. M., Wasik M. A. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc. Natl. Acad. Sci. USA, 97: 4285-4290, 2000.[Abstract/Free Full Text]
  46. Majewski M., Korecka M., Joergensen J., Fields L., Kossev P., Schuler W., Shaw L., Wasik M. A. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation, 75: 1710-1717, 2003.[CrossRef][Medline]
  47. Schuler W., Sedrani R., Cottens S., Häberlin B., Schulz M., Schuurman H. J., Zenke G., Zerwes H. G., Schreier M. H. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation, 64: 36-42, 1997.[CrossRef][Medline]
  48. Lane H. A., Beuvink I., Motoyama A. B., Daly J. M., Neve R. M., Hynes N. E. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol., 20: 3210-3223, 2000.[Abstract/Free Full Text]
  49. Olayioye M. A., Graus-Porta D., Beerli R. R., Rohrer J., Gay B., Hynes N. E. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol. Cell. Biol., 18: 5042-5051, 1998.[Abstract/Free Full Text]
  50. Lane H. A., Thomas G. Purification and properties of mitogen-activated S6 kinase from rat liver and 3T3 cells. Methods Enzymol., 200: 268-291, 1991.[Medline]
  51. Hosoi H., Dilling M. B., Shikata T., Liu L. N., Shu L., Ashmun R. A., Germain G. S., Abraham R. T., Houghton P. J. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res., 59: 886-894, 1999.[Abstract/Free Full Text]
  52. Schuurman H. J., Cottens S., Fuchs S., Joergensen J., Meerloo T., Sedrani R., Tanner M., Zenke G., Schuler W. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation, 64: 32-35, 1997.[CrossRef][Medline]
  53. Dudkin L., Dilling M. B., Cheshire P. J., Harwood F. C., Hollingshead M., Arbuck S. G., Travis R., Sausville E. A., Houghton P. J. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res., 7: 1758-1764, 2001.[Abstract/Free Full Text]
  54. Jiang Y. P., Ballou L. M., Lin R. Z. Rapamycin-insensitive regulation of 4E-BP1 in regenerating rat liver. J. Biol. Chem., 276: 10943-10951, 2001.[Abstract/Free Full Text]
  55. Eng C. P., Sehgal S. N., Vezina C. Activity of rapamycin (AY-22.989) against transplanted tumors. J. Antibiot., 37: 1231-1237, 1984.[Medline]
  56. Houchens D. P., Ovejera A. A., Riblet S. M., Slagel D. E. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur. J. Cancer Clin. Oncol., 19: 799-805, 1983.[CrossRef][Medline]
  57. Geoerger B., Kerr K., Tang C. B., Fung K. M., Powell B., Sutton L. N., Phillips P. C., Janss A. J. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res., 61: 1527-1532, 2001.[Abstract/Free Full Text]
  58. Yu K., Toral-Barza L., Discafani C., Zhang W. G., Skotnicki J., Frost P., Gibbons J. J. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer, 8: 249-258, 2001.[Abstract]
  59. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C. J., Zuelke C., Farkas S., Anthuber M., Jauch K. W., Geissler E. K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med., 8: 128-135, 2002.[CrossRef][Medline]
  60. Grewe M., Gansauge F., Schmid R. M., Adler G., Seufferlein T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res., 59: 3581-3587, 1999.[Abstract/Free Full Text]
  61. Shah S. A., Potter M. W., Ricciardi R., Perugini R. A., Callery M. P. FRAP-p70S6K signaling is required for pancreatic cancer cell proliferation. J. Surg. Res., 97: 123-130, 2001.[CrossRef][Medline]
  62. Kovarik J. M., Kaplan B., Tedesco Silva H., Kahan B. D., Dantal J., Vitko S., Boger R., Rordorf C. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation, 73: 920-925, 2002.[CrossRef][Medline]
  63. Terada N., Franklin R. A., Lucas J. J., Blenis J., Gelfand E. W. Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase. J. Biol. Chem., 268: 12062-12068, 1993.[Abstract/Free Full Text]
  64. Zenke G., Strittmatter U., Fuchs S., Quesniaux V. F., Brinkmann V., Schuler W., Zurini M., Enz A., Billich A., Sanglier J. J., Fehr T. Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action. J. Immunol., 166: 7165-7171, 2001.[Abstract/Free Full Text]
  65. Chung J., Kuo C. J., Crabtree G. R., Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell, 69: 1227-1236, 1992.[CrossRef][Medline]
  66. Harding M. W. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin. Cancer Res., 9: 2882-2886, 2003.[Free Full Text]
  67. Peralba J. M., deGraffenried L., Friedrichs W., Fulcher L., Grünwald V., Weiss G., Hidalgo M. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res., 9: 2887-2892, 2003.[Abstract/Free Full Text]
  68. Stadler W., Logan T., Dutcher J., Hudes G., Park Y., Marshall B., Boni J., Dukart J. A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol., 21: 10a 2002.
  69. O’Donnell A., Faivre S., Judson I., Delbado C., Brock C., Lane H., Shand N., Hazell K., Armand J-P., Raymond E. Phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours. Proc. Am. Soc. Clin. Oncol., 22: 200 2003.



This article has been cited by other articles:


Home page
 Ann OncolHome page
J.-C. Soria, F. A. Shepherd, J.-Y. Douillard, J. Wolf, G. Giaccone, L. Crino, F. Cappuzzo, S. Sharma, S. H. Gross, S. Dimitrijevic, et al.
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
Ann. Onc., October 1, 2009; 20(10): 1674 - 1681.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Mabuchi, C. Kawase, D. A. Altomare, K. Morishige, K. Sawada, M. Hayashi, M. Tsujimoto, M. Yamoto, A. J. Klein-Szanto, R. J. Schilder, et al.
mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
Clin. Cancer Res., September 1, 2009; 15(17): 5404 - 5413.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. K. Anagnostou, G. Bepler, K. N. Syrigos, L. Tanoue, S. Gettinger, R. J. Homer, D. Boffa, F. Detterbeck, and D. L. Rimm
High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma
Clin. Cancer Res., June 15, 2009; 15(12): 4157 - 4164.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Meric-Bernstam and A. M. Gonzalez-Angulo
Targeting the mTOR Signaling Network for Cancer Therapy
J. Clin. Oncol., May 1, 2009; 27(13): 2278 - 2287.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Breuleux, M. Klopfenstein, C. Stephan, C. A. Doughty, L. Barys, S.-M. Maira, D. Kwiatkowski, and H. A. Lane
Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
Mol. Cancer Ther., April 1, 2009; 8(4): 742 - 753.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. R. Schnell, F. Stauffer, P. R. Allegrini, T. O'Reilly, P. M.J. McSheehy, C. Dartois, M. Stumm, R. Cozens, A. Littlewood-Evans, C. Garcia-Echeverria, et al.
Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging
Cancer Res., August 15, 2008; 68(16): 6598 - 6607.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Vazquez-Martin, C. Oliveras-Ferraros, R. Colomer, J. Brunet, and J. A. Menendez
Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)) in human breast carcinoma cells
Ann. Onc., June 1, 2008; 19(6): 1097 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. O'Donnell, S. Faivre, H. A. Burris III, D. Rea, V. Papadimitrakopoulou, N. Shand, H. A. Lane, K. Hazell, U. Zoellner, J. M. Kovarik, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
J. Clin. Oncol., April 1, 2008; 26(10): 1588 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Tabernero, F. Rojo, E. Calvo, H. Burris, I. Judson, K. Hazell, E. Martinelli, S. R. y Cajal, S. Jones, L. Vidal, et al.
Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
J. Clin. Oncol., April 1, 2008; 26(10): 1603 - 1610.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Sleijfer and E. Wiemer
Dose Selection in Phase I Studies: Why We Should Always Go for the Top
J. Clin. Oncol., April 1, 2008; 26(10): 1576 - 1578.
[Full Text] [PDF]

Home page
 The OncologistHome page
C. Gridelli, P. Maione, and A. Rossi
The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer
Oncologist, February 1, 2008; 13(2): 139 - 147.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Schayowitz, G. Sabnis, V. C.O. Njar, and A. M.H. Brodie
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro
Mol. Cancer Ther., January 1, 2008; 7(1): 121 - 132.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Fouladi, F. Laningham, J. Wu, M. A. O'Shaughnessy, K. Molina, A. Broniscer, S. L. Spunt, I. Luckett, C. F. Stewart, P. J. Houghton, et al.
Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors
J. Clin. Oncol., October 20, 2007; 25(30): 4806 - 4812.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. E. Johnson, D. Jackman, and P. A. Janne
Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non Small Cell Lung Cancer
Clin. Cancer Res., August 1, 2007; 13(15): 4628s - 4631s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Mabuchi, D. A. Altomare, M. Cheung, L. Zhang, P. I. Poulikakos, H. H. Hensley, R. J. Schilder, R. F. Ozols, and J. R. Testa
RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model
Clin. Cancer Res., July 15, 2007; 13(14): 4261 - 4270.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. M. Campistol, J. Albanell, W. Arns, I. Boletis, J. Dantal, J. W. de Fijter, S. A. Mortensen, H.-H. Neumayer, O. Oyen, J. Pascual, et al.
Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance
Nephrol. Dial. Transplant., May 1, 2007; 22(suppl_1): i36 - i41.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Gutierrez-Dalmau and J. M. Campistol
The role of proliferation signal inhibitors in post-transplant malignancies
Nephrol. Dial. Transplant., May 1, 2007; 22(suppl_1): i11 - i16.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
C. Xie, R. Patel, T. Wu, J. Zhu, T. Henry, M. Bhaskarabhatla, R. Samudrala, K. Tus, Y. Gong, H. Zhou, et al.
PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr
Int. Immunol., April 1, 2007; 19(4): 509 - 522.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Rojo, L. Najera, J. Lirola, J. Jimenez, M. Guzman, M. D. Sabadell, J. Baselga, and S. R. y Cajal
4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis
Clin. Cancer Res., January 1, 2007; 13(1): 81 - 89.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Cao, T. Subhawong, J. M. Albert, K. W. Kim, L. Geng, K. R. Sekhar, Y. J. Gi, and B. Lu
Inhibition of Mammalian Target of Rapamycin or Apoptotic Pathway Induces Autophagy and Radiosensitizes PTEN Null Prostate Cancer Cells.
Cancer Res., October 15, 2006; 66(20): 10040 - 10047.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Hidalgo, J. C. Buckner, C. Erlichman, M. S. Pollack, J. P. Boni, G. Dukart, B. Marshall, L. Speicher, L. Moore, and E. K. Rowinsky
A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer.
Clin. Cancer Res., October 1, 2006; 12(19): 5755 - 5763.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. W.L. Yee, Z. Zeng, M. Konopleva, S. Verstovsek, F. Ravandi, A. Ferrajoli, D. Thomas, W. Wierda, E. Apostolidou, M. Albitar, et al.
Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Clin. Cancer Res., September 1, 2006; 12(17): 5165 - 5173.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Valmori, V. Tosello, N. E. Souleimanian, E. Godefroy, L. Scotto, Y. Wang, and M. Ayyoub
Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells
J. Immunol., July 15, 2006; 177(2): 944 - 949.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Sosman and I. Puzanov
Molecular targets in melanoma from angiogenesis to apoptosis.
Clin. Cancer Res., April 1, 2006; 12(7): 2376s - 2383s.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. E. O'Reilly, F. Rojo, Q.-B. She, D. Solit, G. B. Mills, D. Smith, H. Lane, F. Hofmann, D. J. Hicklin, D. L. Ludwig, et al.
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
Cancer Res., February 1, 2006; 66(3): 1500 - 1508.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis
Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway
Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Chan, M. E. Scheulen, S. Johnston, K. Mross, F. Cardoso, C. Dittrich, W. Eiermann, D. Hess, R. Morant, V. Semiglazov, et al.
Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer
J. Clin. Oncol., August 10, 2005; 23(23): 5314 - 5322.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Adjei and M. Hidalgo
Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy
J. Clin. Oncol., August 10, 2005; 23(23): 5386 - 5403.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Homicsko, A. Lukashev, and R. D. Iggo
RAD001 (Everolimus) Improves the Efficacy of Replicating Adenoviruses that Target Colon Cancer
Cancer Res., August 1, 2005; 65(15): 6882 - 6890.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Boulay, J. Rudloff, J. Ye, S. Zumstein-Mecker, T. O'Reilly, D. B. Evans, S. Chen, and H. A. Lane
Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer
Clin. Cancer Res., July 15, 2005; 11(14): 5319 - 5328.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Vignot, S. Faivre, D. Aguirre, and E. Raymond
mTOR-targeted therapy of cancer with rapamycin derivatives
Ann. Onc., April 1, 2005; 16(4): 525 - 537.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. K. Goudar, Q. Shi, M. D. Hjelmeland, S. T. Keir, R. E. McLendon, C. J. Wikstrand, E. D. Reese, C. A. Conrad, P. Traxler, H. A. Lane, et al.
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
Mol. Cancer Ther., January 1, 2005; 4(1): 101 - 112.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Raje, S. Kumar, T. Hideshima, K. Ishitsuka, D. Chauhan, C. Mitsiades, K. Podar, S. Le Gouill, P. Richardson, N. C. Munshi, et al.
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
Blood, December 15, 2004; 104(13): 4188 - 4193.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Hidalgo
New Target, New Drug, Old Paradigm
J. Clin. Oncol., June 15, 2004; 22(12): 2270 - 2272.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boulay, A.
Right arrow Articles by Lane, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boulay, A.
Right arrow Articles by Lane, H. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online